Navigation Links
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
Date:2/14/2008

o fight cancer. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Active cellular immunotherapy holds promise because it may provide patients with a meaningful clinical benefit, such as survival, combined with low toxicity. The Company has its headquarters in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dep
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
5. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
6. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
7. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
10. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... N.Y. , Jan. 23, 2015  Lixte Biotechnology Holdings, Inc. ... its Phase I trial of Lixte,s lead compound, LB‑100, is ... John S. Kovach , M.D., the founder ... planned to be completed at a single site. Accrual of ...
(Date:1/23/2015)... 23, 2015   Leatt Corporation  (OTCQB: LEAT), a global ... all forms of sports, including extreme motor sports, and ... today that the UISP Lega Motociclismo Lombardia, an Italian ... to wear a neck brace during its racing competitions.  ...
(Date:1/23/2015)... (NYSE: MNK ) announced today that its ... The open-ended authorization permits the company to repurchase up ... "Funding additional initiatives and seeking attractive business ... pursue a range of focused growth strategies," said ...
Breaking Medicine Technology:Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 2Lixte Biotechnology Holdings Announces Expansion Of Clinical Sites For Its Phase I Trial Of Its Lead Anti-Cancer Compound, LB-100 3Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4
... NEWTON, Mass. , Aug. 5 Microfluidics International Corporation (OTC Bulletin Board: ... on Tuesday, August 10, 2010 , at 8:30am ET . , ... (Logo: http://photos.prnewswire.com/prnh/20090811/NE59652LOGO ) , , ... ) , , , ...
... 5 Cornerstone Therapeutics Inc. (Nasdaq: ... specialty pharmaceutical company focused on acquiring, developing and commercializing ... today announced that its product candidate CRTX-067 is an ... mg hydrocodone polistirex suspension product that will be a ...
Cached Medicine Technology:Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 2Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 3Microfluidics International Corporation to Report Second Quarter 2010 Financial Results on August 10, 2010 4Cornerstone Therapeutics Announces Development of Generic for Tussionex® 2Cornerstone Therapeutics Announces Development of Generic for Tussionex® 3
(Date:1/22/2015)... 22, 2015 Thousand of GranuFlo lawsuits ... recalled its GranuFlo and NaturaLyte dialysis concentrates continue to ... U.S. District Court, District of Massachusetts, Bernstein Liebhard LLP ... Court has remanded a case filed by the state ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Yesterday, ... Bonilla (D-Concord) and Kristin Olsen (R-Modesto) were honored ... leadership in advancing biotechnology, biomedical science, medical device ... Olsen each received the “2014 Life Sciences Champion” ...
(Date:1/22/2015)... Florida (PRWEB) January 22, 2015 IsoComforter, Inc. ... therapy machine with patented IsoTube design to treat specific body ... introduced the most progressive and easy to use patented cold ... post-operative and sports related orthopedic and muscle injuries. IsoComforter ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... American Diabetes Association , ... Welch, Minn. (Vocus) May ... the serious health issues that are associated with diabetes. Type 2 ... those who are 19 years and older. Diabetes has reached epidemic ...
... job loss has impacted most people in every socio-economic ... stimulus combo-packages on BOTOX® Cosmetic and fillers, like Restylane ... feel at the top of their game, improve self ... market and erase unwanted worry lines and reflections of ...
... a Series of Community Discussions on Improving Access to ... Teva Pharmaceuticals USA, the leading generic pharmaceutical company, today ... as part of their Year of Affordable Healthcare campaign ... the YMCA San Francisco, aimed at raising awareness of ...
... Directed Verdict that Rescission was ProperSAN FRANCISCO, May 28 ... General Counsel Seth Jacobs:Today,s verdict is a complete vindication for ... every step of the way. It means that our ... and we acted in good faith. There was no ...
... Inc. (NYSE: DVA ) announced today ... the Company,s Board of Directors. (Logo: ... former President of American Express International, Japan, Asia-Pacific, ... the Consumer Card business across 12 countries, heading ...
... May 28 The London Fire Department has ... breathing apparatus and monitoring systems. Representing a ... largest firefighting service, the order also reflects a ... work closely together to ensure even greater protection ...
Cached Medicine News:Health News:Prairie Island Indian Community Supports Fight Against Diabetes Locally and Nationally 2Health News:Infini Cosmetic Associates Offers Boomer Stimulus Packages to Offset Aging and Help Job Seekers Get a Fresh Start 2Health News:Infini Cosmetic Associates Offers Boomer Stimulus Packages to Offset Aging and Help Job Seekers Get a Fresh Start 3Health News:The Year of Affordable Healthcare Brings Together San Francisco Community Groups to Tackle Healthcare Crisis 2Health News:Pamela M. Arway Joins DaVita Board of Directors 2Health News:London, England Fire Department Places Major Order with Draeger 2
As with all Eschmann products the T20 operating table was designed with 'Simplicity and Intuitiveness' in mind, having drawn influences from leading clinicians of various levels from across the globe...
... carbon fiber c-arm table allows 50 ... brachytherapy, gynecology, gastroenterology, cardiovascular, orthopedic, ENT, ... design allows easy access for all ... 16-inch elevating travel, 16-inch longitudinal travel, ...
... imaging table is a fully digital imaging ... and advanced patient data management system. The ... the industry providing unsurpassed access for both ... to either a right- or left- hand ...
... Designed for procedures where stability, ... are essential. A cantilevered low attenuation ... ceiling-suspended C-Arms. The radiolucent area is ... fluoroscopic visualization and unobstructed C-Arm positioning. ...
Medicine Products: